GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Asset Turnover

Consun Pharmaceutical Group (HKSE:01681) Asset Turnover : 0.23 (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Consun Pharmaceutical Group's Revenue for the six months ended in Jun. 2024 was HK$1,366 Mil. Consun Pharmaceutical Group's Total Assets for the quarter that ended in Jun. 2024 was HK$5,967 Mil. Therefore, Consun Pharmaceutical Group's Asset Turnover for the quarter that ended in Jun. 2024 was 0.23.

Asset Turnover is linked to ROE % through Du Pont Formula. Consun Pharmaceutical Group's annualized ROE % for the quarter that ended in Jun. 2024 was 21.65%. It is also linked to ROA % through Du Pont Formula. Consun Pharmaceutical Group's annualized ROA % for the quarter that ended in Jun. 2024 was 14.42%.


Consun Pharmaceutical Group Asset Turnover Historical Data

The historical data trend for Consun Pharmaceutical Group's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Asset Turnover Chart

Consun Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.47 0.50 0.48 0.49

Consun Pharmaceutical Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.29 0.22 0.28 0.23

Competitive Comparison of Consun Pharmaceutical Group's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Consun Pharmaceutical Group's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Consun Pharmaceutical Group's Asset Turnover falls into.



Consun Pharmaceutical Group Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Consun Pharmaceutical Group's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=2833.013/( (5463.393+6024.528)/ 2 )
=2833.013/5743.9605
=0.49

Consun Pharmaceutical Group's Asset Turnover for the quarter that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=1365.648/( (6024.528+5910.084)/ 2 )
=1365.648/5967.306
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Consun Pharmaceutical Group  (HKSE:01681) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Consun Pharmaceutical Group's annulized ROE % for the quarter that ended in Jun. 2024 is

ROE %**(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=860.728/3975.6375
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(860.728 / 2731.296)*(2731.296 / 5967.306)*(5967.306/ 3975.6375)
=Net Margin %*Asset Turnover*Equity Multiplier
=31.51 %*0.4577*1.501
=ROA %*Equity Multiplier
=14.42 %*1.501
=21.65 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Consun Pharmaceutical Group's annulized ROA % for the quarter that ended in Jun. 2024 is

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=860.728/5967.306
=(Net Income / Revenue)*(Revenue / Total Assets)
=(860.728 / 2731.296)*(2731.296 / 5967.306)
=Net Margin %*Asset Turnover
=31.51 %*0.4577
=14.42 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Consun Pharmaceutical Group Asset Turnover Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Consun Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Executives
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Gl China Long Equity Opportunities Fund Lp 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
An Meng 2101 Beneficial owner
Zhang Lihua 2202 Interest of your spouse
Double Grace International Limited 2101 Beneficial owner
Li Qian 2101 Beneficial owner
An Yubao 2101 Beneficial owner
Central Success Developments Limited 2101 Beneficial owner
Aali Resources Limited 2201 Interest of corporation controlled by you
Bos Trustee Limited 2301 Trustee
Bos Trustee Limited As Trustee 2201 Interest of corporation controlled by you

Consun Pharmaceutical Group Headlines

No Headlines